BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a KRAS G12C inhibitor for antitumor; BEBT-808, an oral small molecule GLP-1R full agonist for metabolic disease; BEBT-809, a GPR75 pathway inhibitor for metabolic disease; and BEBT-508, a small nucleic acid drug. The company was founded in 2012 and is based in Guangzhou, China.
Metrics to compare | 688759 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688759PeersSector | |
|---|---|---|---|---|
P/E Ratio | −102.7x | 11.0x | −0.5x | |
PEG Ratio | 0.68 | 0.08 | 0.00 | |
Price/Book | 73.0x | 2.0x | 2.6x | |
Price / LTM Sales | - | 5.3x | 3.2x | |
Upside (Analyst Target) | - | 32.5% | 45.2% | |
Fair Value Upside | Unlock | 25.2% | 6.4% | Unlock |